SMS Pharmaceuticals Q1 FY27 profit rises to Rs 21.1 cr

Q1 FY27 results: profit improves on better operating performance

SMS Pharmaceuticals reported a stronger standalone performance in Q1 FY27 (quarter ended June 30, 2026), backed by higher revenue and a modest improvement in operating margins. Revenue rose year-on-year to Rs 207.0 crore, compared with Rs 196.0 crore in Q1 FY26. Standalone net profit increased to Rs 21.1 crore from Rs 18.2 crore a year ago. The company’s quarterly update indicates that profitability expanded alongside revenue, with EBITDA rising and margins ticking up.

Revenue growth: Q1 top line increases to Rs 207 crore

The company’s Q1 FY27 standalone revenue came in at Rs 207.0 crore, up from Rs 196.0 crore in the comparable quarter last year. The year-on-year growth was supported by stronger business momentum as the company entered FY27. While the disclosure does not provide segment-level details for the quarter, it positions the quarter as a solid start to the year. Investors typically track revenue growth and margin movement for API-focused businesses due to sensitivity to product mix, pricing, and capacity utilisation.

EBITDA up to Rs 41.9 crore; margin expands to 20.24%

SMS Pharmaceuticals reported Q1 FY27 EBITDA of Rs 41.9 crore, compared with Rs 38.9 crore in Q1 FY26. The EBITDA margin improved to 20.24% from 19.82%, a 42 basis points expansion year-on-year. Margin expansion alongside revenue growth generally signals improved operating leverage or a more favourable mix, though the company’s disclosure in the provided text does not attribute the change to specific factors. Still, the margin move is a key datapoint for investors assessing the quality of earnings.

Net profit rises to Rs 21.1 crore in Q1 FY27

Standalone net profit for the quarter increased to Rs 21.1 crore from Rs 18.2 crore in Q1 FY26. The improvement aligns with the reported EBITDA increase and margin expansion. Net profit growth is particularly watched in quarters where revenue growth is moderate, as it can reflect tighter cost control and better conversion of operating profit into bottom-line earnings. The update frames the quarter as one marked by “robust revenue growth and expanding profitability.”

Key numbers at a glance

The table below summarises the core standalone operating metrics disclosed for Q1 FY27 versus Q1 FY26.

Regulatory pipeline: FY26 filings and FY27 submission target

Beyond quarterly performance, the company highlighted its regulatory filing activity. It completed 12 Drug Master File (DMF) and Certificate of Suitability (CEP) filings in FY26. For FY27, it has set a target of 10 submissions. For API manufacturers, DMF and CEP filings are often monitored because they can expand addressable markets, support customer onboarding, and widen product opportunities across regulated geographies.

Dividend update: board recommends Rs 0.40 per share for FY26

For the financial year ended March 31, 2026, the Board of Directors recommended a final dividend of Rs 0.40 (40%) per share. The disclosure in the provided text does not specify record date or payment date. Dividend actions are typically evaluated alongside reinvestment requirements and ongoing capex plans, especially in manufacturing-led pharma businesses.

Stock snapshot and listings

SMS Pharmaceuticals is listed on NSE under the symbol SMSPHARMA and on BSE under code 532815. The stock snapshot in the provided text shows a BSE price of Rs 424.50, up Rs 2.95 (0.70%) at 04:01 PM on July 3. The same dataset also references a current share price of Rs 421.45 and notes shares trading around Rs 420 in a separate market commentary. These snapshots reflect different points in time but broadly place the stock in the Rs 420-425 range in the context provided.

Why the Q1 margin uptick matters for an API manufacturer

In API and intermediates manufacturing, small changes in margin can materially change quarterly profit because of the scale of fixed costs. In Q1 FY27, EBITDA margin increased to 20.24% from 19.82%, while EBITDA rose to Rs 41.9 crore. Alongside the profit increase to Rs 21.1 crore, the numbers indicate that earnings improved faster than revenue in the year-on-year comparison presented. Separately, the FY26 DMF and CEP filing count and the FY27 target provide a read-through on the company’s focus on expanding its product and regulatory footprint.

Conclusion

SMS Pharmaceuticals opened FY27 with higher standalone revenue of Rs 207.0 crore and net profit of Rs 21.1 crore, supported by an EBITDA margin improvement to 20.24%. The company also reiterated its regulatory filing cadence, with 12 DMF and CEP filings completed in FY26 and a target of 10 submissions in FY27. Investors will typically watch for follow-through on margins and filing activity in subsequent quarters, along with any updates linked to the FY26 final dividend recommendation of Rs 0.40 per share.